PALI Palisade Bio Inc

$PALI The market has already digested the UEG data and is now in wait-and-see mode for real validation. The current price of ~$1.20 reflects exactly that: skepticism toward early signals + a long wait until the key data. The main catalyst is 2H 2027 (12-week ASCENTRA-UC data). If it confirms activity (especially with the biomarker and hints of an effect on fibrosis), the re-rating potential will be very large. If not — a sharp downward revaluation. This is a classic high-risk / high-reward clinical-stage biotech with roughly a 12-month horizon until the main answer.The UEG news is essentially not new. • The price targets are a bet on success in ~12 months. Additional risk: further dilution remains possible if the company needs to raise more capital before the Phase 2 readouts. 🟩✅ On November 12, positive news regarding MDXH will emerge. Keep an eye on this stock and buy MDXH.

$PALI interesting UEGW. They are showcasing their product well. Phase 2 data would be the litmus test. Tolerability and pharmacokinetics are well established.

$PALI 🏥 Palisade Bio, Inc. reported Phase 1b Crohn’s disease data for PALI-2108 showing a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days, alongside translational evidence. Market-relevant event

$PALI had news maybe a bounce at 1.32 $YMAT 2.36 keybreak. $HTZ no more fun Unless 2.10/2.29 above

$PALI Each earning I am doing in scalping is to accumulate more and more $PALI. Once approved and commercialize we will be above 10USD. 3-4 years... I can wait...